Ignite Creation Date:
2024-05-05 @ 5:01 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00369343
Status:
COMPLETED
Last Update Posted:
2012-05-07
First Post:
2006-08-25
Brief Title:
Study Evaluating Desvenlafaxine Succinate Sustained Release DVS SR Versus Placebo in Peri- and Postmenopausal Women
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
A Multicenter Randomized 8-week Double-blind Placebo-controlled Study Followed by a 6-month Open-label Extension to Evaluate the Efficacy and Safety of DVS SR in Peri- and Postmenopausal Women With Major Depressive Disorder
Status:
COMPLETED
Status Verified Date:
2012-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Desvenlafaxine succinate DVS is a potent and selective serotonin and norepinephrine reuptake inhibitor SNRI The sustained-release SR formulation DVS SR is being studied in the development program for the treatment of major depressive disorder MDD for vasomotor symptoms VMS associated with menopause and for pain associated with peripheral diabetic neuropathy as well as for the treatment of fibromyalgia syndrome This study will investigate the safety efficacy and tolerability of DVS SR in women with MDD who are peri- and postmenopausal
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None